Subtitle
Treatment of primary or recurrent non-resectable pancreatic cancer with proton beam irradiation combined with gemcitabine-based chemotherapy.
Subtitle
Treatment of primary or recurrent non-resectable pancreatic cancer with proton beam irradiation combined with gemcitabine-based chemotherapy.
Proto therapy Time
July and August 2023
Executive summary
This study reported results of 25 patients with localized nonresectable pancreatic cancer (15 patients) or local recurrent disease (10 patients) treated with chemoradiation using PBT. The median progression-free survival was 5.9 months and median overall survival was 11.0 months. Four grade 3 and 4 acute adverse events were reported.